MacroGenics (NASDAQ:MGNX) Downgraded by Cowen

Cowen lowered shares of MacroGenics (NASDAQ:MGNXGet Rating) from an outperform rating to a market perform rating in a report published on Tuesday morning, MarketBeat Ratings reports.

Other equities analysts have also recently issued reports about the company. SVB Leerink dropped their target price on MacroGenics from $15.00 to $12.00 and set an outperform rating for the company in a report on Tuesday, August 9th. Citigroup increased their target price on MacroGenics from $13.00 to $16.00 and gave the stock a buy rating in a report on Monday, August 29th. Barclays dropped their target price on MacroGenics to $8.00 in a report on Monday, August 15th. StockNews.com started coverage on MacroGenics in a report on Wednesday, October 12th. They issued a hold rating for the company. Finally, HC Wainwright increased their price target on MacroGenics from $11.00 to $12.00 and gave the stock a buy rating in a research report on Monday, November 7th. Five investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, MacroGenics has a consensus rating of Moderate Buy and a consensus price target of $10.89.

MacroGenics Stock Down 0.2 %

MacroGenics stock opened at $6.17 on Tuesday. The business has a 50 day moving average price of $4.64 and a two-hundred day moving average price of $4.02. MacroGenics has a 12 month low of $2.13 and a 12 month high of $19.73.

Insider Buying and Selling at MacroGenics

In other news, major shareholder Target N. V. Biotech acquired 250,000 shares of the firm’s stock in a transaction on Friday, October 21st. The shares were purchased at an average cost of $4.63 per share, for a total transaction of $1,157,500.00. Following the transaction, the insider now owns 7,979,963 shares of the company’s stock, valued at $36,947,228.69. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. In other news, major shareholder Target N. V. Biotech acquired 250,000 shares of the firm’s stock in a transaction on Friday, October 21st. The shares were purchased at an average cost of $4.63 per share, for a total transaction of $1,157,500.00. Following the transaction, the insider now owns 7,979,963 shares of the company’s stock, valued at $36,947,228.69. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Target N. V. Biotech acquired 168,422 shares of the firm’s stock in a transaction on Wednesday, October 19th. The stock was purchased at an average price of $3.70 per share, for a total transaction of $623,161.40. Following the completion of the transaction, the insider now directly owns 7,443,986 shares in the company, valued at approximately $27,542,748.20. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 668,422 shares of company stock worth $2,870,661. Insiders own 7.90% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Nisa Investment Advisors LLC boosted its position in shares of MacroGenics by 692.3% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,150 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 4,500 shares during the last quarter. Denali Advisors LLC bought a new position in shares of MacroGenics in the 3rd quarter worth $25,000. Teacher Retirement System of Texas bought a new position in shares of MacroGenics in the 1st quarter worth $89,000. Chicago Partners Investment Group LLC bought a new position in shares of MacroGenics in the 2nd quarter worth $32,000. Finally, E Fund Management Co. Ltd. bought a new position in shares of MacroGenics in the 1st quarter worth $92,000.

About MacroGenics

(Get Rating)

MacroGenics, Inc, a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.

Read More

Analyst Recommendations for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.